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Introduction: Helicobacter pylori (H. pylori)i sa
non-invasive microorganism causing intense gastric
mucosal inflammatory and immune reaction. H.
pylori-induced gastric mucosal cytokine overproduc-
tion has been clearly documented previously. The
stomach has a large surface area and continuous
spill-over of locally produced cytokines into the
blood stream is a possibility. There are few and
conflicting data on circulatory proinflammatory cy-
tokine levels in patients with H. pylori infection.
Materials and methods: Forty-two dyspeptic patients
were enrolled into the study. The presence of
H. pylori infection was diagnosed with antral histo-
pathologic examination. After overnight fasting;
serum samples were obtained from each patient to
determine circulating interleukin (IL)-6, IL-8 and
tumor necrosis factor-a (TNF-a) levels.
Results: H. pylori was shown in 30 cases using
Giemsa stain in antral histopathologic evaluation.
Twelve cases were negative for H. pylori staining.
Both the age and sex distribution had an insignificant
difference in both H pylori-positive and H. pylori-
negative groups. The mean circulatory levels of IL-6,
IL-8 and TNF-a in both groups were not different. The
situation was same in respect to the serum levels of
these cytokines and the degree of inflammation,
H. pylori density and activation scores according to
Sydney classification.
Conclusion: We could not show elevated circulatory
levels of IL-6, IL-8 and TNF-a in H. pylori-infected
cases. We believe that H. pylori-related cytokine
activation become concentrated on gastric mucosa
and this pathogen-induced local inflammatory cas-
cade does not cause changes in circulatory levels of
these cytokines. Moreover, there is no correlation
between the levels of serum cytokines and Sydney
parameters.
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Introduction
In many gastrointestinal infections, the inflammatory
response induced by the pathogen can be an
important contributor to mucosal damage and epi-
thelial dysfunction. Possibly the best example of this
is the infection with Heliobacter pylori microorgan-
isms. H. pylori leads to mucosal increases in many
proinflammatory and immunoregulatory cytokines,
and also increases in members of the chemokine
group of peptides.
1 As a most probable target in H.
pylori infection, and a major interface between the
host and pathogen, the epithelial cell initiates acute
mucosal inflammation and interacts with the other
mucosal cell populations via a cytokine network.
2
These two responses may be regulated differentially
following induction of cytokines involved in the
inflammatory cascade, including tumor necrosis fac-
tor-a (TNF-a), interleukin (IL)-1, IL-6, and IL-8.
36
The stomach has a large surface area. A suggestion
that the chronic gastric mucosal inflammation
induced by H. pylori potentially may have systemic
effects based on increases in serum proinflamma-
tory cytokines seems not to be bizarre. Although
cytokine-based gastric mucosal immune response
to H. pylori infection has been documented very
well, very minute data on circulating levels of
particular proinflammatory cytokines are available.
Moreover, the present few data are contradictory.
710
In our study, we investigated circulating levels of
IL-8, IL-6 and TNF-a in patients with H. pylori
infection.
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25Research design and methods
Patients
Forty-two patients with dyspeptic symptoms enrolled
into the study. Patients who received anti-bacterial
treatment for H. pylori and anti-ulcer drugs 1 month
prior to the study or who had undergone vagotomy
or stomach resection were excluded.
Assessment of the state of H. pylori infection
The state of H. pylori infection was assessed histo-
logically. The biopsy specimens were fixed in 10%
formalin and embedded in paraffin. H. pylori was
determined by Giemsa staining. The density of
H. pylori was graded as ‘none’, ‘mild’, ‘moderate’,
and ‘severe’ according to the Sydney system,
11 and
scored on a 0/3 scale. When at least one of the two
biopsies of each patient yielded a positive result, the
patient was considered as positive for H. pylori.
Histological assessment of gastritis
Sections were also stained with hematoxylin and
eosin. The severity of chronic and acute inflamma-
tion, atrophy, and intestinal metaplasia was graded as
‘none’, ‘mild’, ‘moderate’, and ‘severe’ according to
the Sydney system and scored on a 0/3 scale.
11
IL-8, IL-6 and TNF-a assays
Blood samples were taken after overnight fast and
after 30 min in the supine position to determine
serum IL-8, IL-6 and TNF-a. Samples were stored at
/208C. Serum cytokine concentrations were deter-
mined in triplicate using a commercial enzyme-linked
immunosorbent assay (Immulite IL-8, Immulite IL-6,
Immulite TNF-a; DPC, Los Angeles, CA, USA). The
sensitivities of these assays are approximately 2 pg/
ml, 1 pg/ml and 1.7 pg/ml for IL-8, IL-6 and TNF-a,
respectively.
Statistical analysis
Results are expressed as the mean9 /standard devia-
tion. In the comparison between groups, statistically
significant differences were assessed by the chi-
square test and the Mann/Whitney U-test. pB/0.05
was considered statistically significant.
Results
Our study group had a mean age of 44.59 /11.9 years
(20/65 years). The male to female ratio was 20/22.
The presence of H. pylori was seen in 32 patients.
Twelve cases were negative for the presence of
H. pylori. Both the age and sex distribution had an
insignificant difference in both groups. The Sydney
classification scores in our cases are presented in
Table 1. None of our cases had severe inflammation
and atrophy. The situation was not different in
respect to serum levels of these cytokines and the
degree of inflammation, H. pylori density and activa-
tion scores according to the Sydney system (p /0.05)
(Table 2).
We could not detect statistically significant differ-
ences in the serum levels of these cytokines with
respect to the presence or absence of H. pylori
(p /0.05).
Discussion
In the present study, we scrutinized the levels of
circulatory cytokines, which may theoretically in-
crease as a consequence of intense gastric mucosal
cytokine activation. We know that infection with
H. pylori leads to increases in many mucosal proin-
flammatory and immunregulatory cytokines such as
IL-6, IL-8, IL-1b, TNF-a, interferon-g, and platelet-
activating factor.
1 However, the primary modulator
cytokine in H. pylori-associated gastritis is IL-8.
12
H. pylori pathogenicity island encoding for Cag A
protein and other virulence factors increases expres-
sion of IL-8, which in turn triggers the neutrophilic
infiltration and induces cytokine release adherence to
the epithelium.
13 If we consider the total gastric
surface area, which is nearly 700 cm
2, it is not unwise
to think that H. pylori-associated gastric local muco-
sal response may have systemic effects.
14 As an
example; one of these effects may be through
hypergastrinemia. TNF-a increases serum gastrin
levels by decreasing the somatostatin content in D
cells in animal models.
15 IL 8 increases the basal
gastrin release from canine G cells.
16,17 As is generally
known, gastrin has many extra-gastric effects, espe-
cially on intestinal and colonic epithelial growth and
enteric immune response.
18,19
In the present study we aimed to investigate
whether we can show increased serum proinflamma-
tory cytokines such as TNF-a, IL-8 and IL-6 in
H. pylori-infected patients without systemic diseases.
We could not demonstrate any increase in circulatory
cytokines in H. pylori-positive patients. Although
Table 1. Sydney scores of our patients
Score 0 Score 1 Score 2 Score 3
H. pylori 12 (28.6) 25 (59.5) 5 (11.9) /
Inflammation / 15 (35.7) 27 (64.3) /
Activation 22 (52.4) 20 (47.6) / /
Atrophy / / / /
Metaplasia 40 (95.2) 2 (4.8) / /
Data presented as n (%).
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well with the intensity of gastric mucosal inflamma-
tion, serum cytokine levels did not show correlation
with Sydney parameters, including the gastric epithe-
lial inflammatory scores, H. pylori density and
activation, in the present study.
3 In the literature,
some authors reported increased circulatory TNF-a
levels while serum IL-8 levels remained normal in
H. pylori-infected persons.
7 Some others reported
elevated serum TNF-a levels in patients with CagA-
positive H. pylori infection.
8 IL-1, IL-6 and IL-8 were
all also elevated in Cag A-positive cases.
20,21 We did
not determine the Cag A status of our patients. Thus,
we do not know whether most or all of our patients
were infected with a Cag A-negative strain. However,
we know that our patients neither had endoscopic
sign of gastroduodenal ulceration nor had severe
gastritis on histopathology. Therefore we possibly
had patients infected with less pathogenic strains of
this bacterium such as with Cag A-negative H. pylori.
The other possibility may be the inhibition of further
inflammation by a gastric protective cytokine IL-10.
22
Although we do not measure its levels on gastric
mucosal extracts and circulation, we know that IL-10
secreted by gastric mucosa has inhibitory effects on
gastric mucosal immune response associated with
local proinflammatory cytokine activation.
As a result of contradictory reports, including ours,
we do not know whether the continuous spill-over of
cytokines into the blood stream could be possible as
a consequence of gastric mucosal cytokine activation
and increased synthesis. If true, this may be a
potential threat in patients with H. pylori infection
for some ‘extra-gastric’ pathologies, such as coronary
heart disease, primary Raynaud phenomenon, side-
ropenic refractory anemia and delayed growth in
children.
2328 We think that further studies are
needed to make firm conclusions on H. pylori-
induced changes in the circulatory cytokine levels.
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